Andersen, Johanna B., Sharmin, Sifat, Lefort, Mathilde, Koch-Henriksen, Nils, Sellebjerg, Finn, Sørensen, Per Soelberg, Hilt Christensen, Claudia C., Rasmussen, Peter V., Jensen, Michael B., Frederiksen, Jette L., Bramow, Stephan, Mathiesen, Henrik K., Schreiber, Karen I., Horakova, Dana, Havrdova, Eva K., Alroughani, Read, Izquierdo, Guillermo, Eichau, Sara, Ozakbas, Serkan, Patti, Francesco, Onofrj, M, Lugaresi, A, Terzi, M, Grammond, P, Grand Maison, F, Yamout, B, Prat, A, Girard, M, Duquette, P, Boz, C, Trojano, M, McCombe, P, Slee, M, Lechner-Scott, Jenette, Turkoglu, R, Sola, P, Ferraro, D, Granella, F, Shaygannejad, V, Prevost, J, Skibina, O, Solaro, C, Karabudak, R, Wijmeersch, BV, Csepany, T, Spitaleri, D, Vucic, S, Casey, R, Debouverie, M, Edan, G, Ciron, J, Ruet, A, Sèze, JD, Maillart, E, Zephir, H, Labauge, P, Defer, G, Lebrun, C, Moreau, T, Berger, E, Clavelou, P, Pelletier, J, Stankoff, B, Gout, O, Thouvenot, E, Heinzlef, O, Al-Khedr, A, Bourre, B, Casez, O, Cabre, P, Montcuquet, A, Wahab, A, Camdessanché, JP, Marousset, A, Patry, I, Hankiewicz, K, Pottier, C, Maubeuge, N, Labeyrie, C, Nifle, C, Leray, E, Laplaud, DA, Butzkueven, H, Kalincik, T, Vukusic, S, Magyari, M. Elsevier; 2021. The effectiveness of natalizumab vs fingolimod - A comparison of international registry studies.

De Brouwer, Edward, Becker, Thijs, Kappos, Ludwig, Sola, Patrizia, Cartechini, Elisabetta, Lechner-Scott, Jeannette, Alroughani, Raed, Gerlach, Oliver, Kalincik, Tomas, Granella, Franco, Grand'Maison, Francois, Bergamaschi, Roberto, Moreau, Yves, José Sá, M, Van Wijmeersch, B, Soysal, A, Sanchez-Menoyo, JL, Solaro, C, Boz, C, Iuliano, G, Buzzard, K, Aguera-Morales, E, Terzi, M, Havrdova, Eva Kubala, Trivio, TC, Spitaleri, D, Van Pesch, V, Shaygannejad, V, Moore, F, Oreja-Guevara, C, Maimone, D, Gouider, R, Csepany, T, Ramo-Tello, C, Trojano, Maria, Peeters, L, Eichau, Sara, Ozakbas, Serkan, Onofrj, Marco, Grammond, Pierre, Kuhle, Jens. Elsevier; 2021. Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression.

Roos, Izanne, Leray, Emmanuelle, Eichau, Sara, Onofrj, Marco, Lugaresi, Alessandra, Prat, Alexandre, Girard, Marc, Grammond, Pierre, Sola, Patrizia, Ferraro, Diana, Ozakbas, Serkan, Bergamaschi, Roberto, Frascoli, Federico, Sá, Maria José, Cartechini, E, Boz, C, Granella, F, Hupperts, R, Terzi, M, Lechner-Scott, Jeannette, Spitaleri, D, Van Pesch, V, Soysal, A, Casey, Romain, Olascoaga, J, Prevost, J, Aguera-Morales, E, Slee, M, Csepany, T, Turkoglu, R, Sidhom, Y, Gouider, R, Van Wijmeersch, B, McCombe, P, Brown, J. William L., Macdonell, R, Coles, A, Malpas, CB, Butzkueven, H, Vukusic, S, Kalincik, T, , , Horakova, Dana, Havrdova, Eva K., Trojano, Maria, Patti, Francesco, Izquierdo, Guillermo. Oxford University Press; 2020. Delay from treatment start to full effect of immunotherapies for multiple sclerosis.

Roos, Izanne, Leray, Emmanuelle, Izquierdo, Guillermo, Eichau, Sara, Edan, Gilles, Prat, Alexandre, Girard, Marco, Duquette, Pierre, Onofrj, Marco, Lugaresi, Alessandra, Grammond, Pierre, Ciron, Jonathon, Frascoli, Federico, Ruet, A, Ozakbas, S, De Seze, J, Louapre, C, Zephir, H, Sá, MJ, Sola, P, Ferraro, D, Labauge, P, Defer, G, Casey, Romain, Bergamaschi, R, Lebrun-Frenay, C, Boz, C, Cartechini, E, Moreau, T, Laplaud, D, Lechner-Scott, Jeanette, Grand’Maison, F, Gerlach, O, Terzi, M, Brown, J. William L., Granella, F, Alroughani, R, Iuliano, G, Van Pesch, V, Van Wijmeersch, B, Spitaleri, DLA, Soysal, A, Berger, E, Prevost, J, Aguera-Morales, E, Horakova, Dana, McCombe, P, Castillo Triviño, T, Clavelou, P, Pelletier, J, Turkoglu, R, Stankoff, B, Gout, O, Thouvenot, E, Heinzlef, O, Sidhom, Y, Havrdova, Eva Kubala, Gouider, R, Csepany, T, Bourre, B, Al Khedr, A, Casez, O, Cabre, P, Montcuquet, A, Wahab, A, Camdessanche, JP, Maurousset, A, Debouverie, Marc, Patry, I, Hankiewicz, K, Pottier, C, Maubeuge, N, Labeyrie, C, Nifle, C, Coles, A, Malpas, CB, Vukusic, S, Butzkueven, H, Trojano, Maria, Kalincik, T, Patti, Francesco. Sage Publications; 2021. Determinants of therapeutic lag in multiple sclerosis.